Fig. 6: MFF might be a target for ovarian cancer treatment.

a CPT1A and MFF was detected by WB in ovarian cancer cells (left). The WB bands density were quantified with ImageJ and normalized to β-tubulin. The expression relationship of CPT1A and MFF was analyzed (right). b CPT1A and MFF in tissue array were analyzed by IHC. Representatives images of ovarian cancer tissue, paracancerous tissue and normal ovarian tissue were shown (Scale bar = 200 μm, left). The expression relationship between CPT1A and MFF in tissue array was analyzed on the basis of H-score (right). c Based on H-score, the relative expression of MFF in normal ovarian tissues and various ovarian cancer and paracancerous tissues was analyzed (n = 100 cases). d Overall survival and progression-free survival rates were analyzed with Kaplan-Meier survival analysis for the relationship between survival time and MFF expression in ovarian cancer patients using the online tool (http://kmplot.com/analysis/). e MFF knockdown and control SKOV-3 cells were injected subcutaneously on the left and right flank of nude mice, respectively. Growth curves were prepared from tumor volumes measured at indicated times post cell injection (mean ± SD, n = 5 nude mice). Insets show MFF knockdown and control tumors. Scale bars, 12 mm. f At the end of the experiment, tumors were harvested and weighed, n = 5 nude mice. g Xenografts were sectioned and stained with anti-Ki-67 and anti-p21 antibodies (left). Quantitative analysis of Ki-67-positive and p21-positive cells staining area were performed with ImageJ (n = 3 for each group, right). Data represent the mean ± SD; *p < 0.05; **p < 0.01. ***p < 0.001, n.s. indicates no significant difference compared with the control groups or as indicated. Scale bars, 50 μm.